Skip to main content
. Author manuscript; available in PMC: 2010 Sep 7.
Published in final edited form as: Int J Tuberc Lung Dis. 2009 Sep;13(9):1148–1153.

Table 1.

Resistance to First- and Second - Line Tuberculosis Drugs in New and Previously treated Cases

Resistance N=605 Total
N=605 (100%)

New cases
n=222 (36,7%)
Previously treated Cases
n=383 (63,3%)
Sensitive TB 73 (32,88%) 41 (10,70%) 114 (18,8%)

Total DR-TB 149 (67,12%) 342 (89,30%) 491(81,2%)

Resistance for I Line TB Drugs

Total Mono DR-TB 69 (31,08%) 61 (15,93%) 130 (21,5%)

H 8 (3,6%) 12 (3,13%) 20 (3,3%)
R 1 (0,45%) 3 (0,8%) 4 (0,7%)
S 60 (27,03%) 45 (11,75%) 105 (17,3%)
E 0 1 (0,3%) 1 (0,2%)

Total PDR-TB 23 (10,36%) 44 (11,5%) 67 (11,1%)

H+S 19 (8,6%) 33 (8,62,%) 52 (8,6%)
H+E 0 0 0
R+S 2 (0,9%) 3 (0,8%) 5 (0,8%)
R+E 0 1 (0,3%) 1 (0,2%)
S+E 1 (0,45%) 2 (0,52%) 3 (0,5%)
H+S+E 0 4 (1,04%) 4 (0,7%)
R+S+E 1 (0,45%) 1 (0,3%) 2 (0,3%)

Total MDR-TB 51 (22,97%) 210 (54,83%) 261 (43,1%)

H+R 2 (0,9%) 13 (3,4%) 15 (2,5%)
H+R+S 26 (11,71%) 85 (22,2%) 111 (18,3%)
H+R+E 0 7 (1,83%) 7 (1,2%)
H+R+S+E 23 (10,36%) 105 (27,4%) 128 (21,1%)

Resistance for II Line TB Drugs

Amk 11 (4,95%) 43 (11,23%) 54 (8,9%)
Cm 12 (5,4%) 39 (10,18%) 51 (8,4%)
Ofx 14 (6,3%) 61 (15,93%) 75 (12,4%)
Eto 37 (16,7%) 104 (27,15%) 141 (23,3%)
Cs 11 (4,95%) 37 (9,66%) 48 (7,9%)
PAS 10 (4,5%) 26 (6,8%) 36 (6,0%)

Total XDR-TB 6 (2,70%) 27 (7,04%) 33 (5,5%)